WDNA
WisdomTree BioRevolution Fund
Price Chart
Latest Quote
$23.96
+0.79 (+3.40%)
Current Price
| Previous Close | $23.18 |
| Open | $23.21 |
| Day High | $23.96 |
| Day Low | $23.21 |
| Volume | 2,618 |
Fund Information
| Quarterly Dividend / Yield | N/A / 3.21% |
| Net Assets | $4.80M |
| Expense Ratio | 0.45% |
| Category | Health |
| Fund Family | WisdomTree |
| Net Asset Value | $23.18 |
| Premium/Discount | 3.38% |
| Quarterly Dividend Yield | 3.21% |
| P/E Ratio | 29.13 |
| Exchange | BTS |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $23.22 |
| SMA50 | $23.21 |
| SMA200 | $19.68 |
| RSI | 59.88 |
| ATR | 0.5079 |
| Rel Volume | 1.30 |
Performance History
| Week | +2.53% |
| Month | +0.06% |
| Quarter | +22.47% |
| 6 Months | +35.81% |
| YTD | +41.63% |
| Year | +43.60% |
| 3 Years | +81.02% |
| 5 Years | +1.02% |
| 10 Years | +2.23% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $23.96 | 2,600 |
| 2026-10-26 | $23.17 | 2,500 |
| 2026-10-23 | $23.05 | 100 |
| 2026-10-22 | $23.18 | 1,500 |
| 2026-10-21 | $23.51 | 1,200 |
| 2026-10-20 | $23.37 | 5,300 |
| 2026-10-19 | $22.69 | 2,800 |
| 2026-10-16 | $22.31 | 2,400 |
| 2026-10-15 | $23.21 | 700 |
| 2026-10-14 | $22.80 | 1,600 |
| 2026-10-13 | $22.67 | 1,300 |
| 2026-10-12 | $23.01 | 3,100 |
| 2026-10-09 | $23.50 | 1,700 |
| 2026-10-08 | $22.60 | 1,800 |
| 2026-10-07 | $22.78 | 2,000 |
| 2026-10-06 | $22.93 | 2,600 |
| 2026-10-05 | $24.31 | 1,100 |
| 2026-10-02 | $23.68 | 2,500 |
| 2026-10-01 | $23.63 | 2,100 |
| 2026-09-30 | $24.10 | 1,000 |
| 2026-09-29 | $24.13 | 1,200 |
| 2026-09-28 | $23.95 | 900 |
About WisdomTree BioRevolution Fund
The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.
đ° Latest News
No news articles available at the moment. Check back later for updates on WDNA.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.